Johnson & Johnson: human testing of its coronavirus vaccine to begin by September
Johnson & Johnson announced human testing of its experimental vaccine for the coronavirus will begin by September and it could be available for emergency use authorization in early 2021.
J&J also said it has committed more than $1 billion of investment in partnership with the federal Biomedical Advanced Research and Development Authority, which is part of the Department of Health and Human Services, to co-fund vaccine research.
J&J’s lead vaccine candidate will enter a phase 1 human clinical study by September, the company said, and clinical data on its effects is expected before the end of the year. If the vaccine works well, the company said it could be available for emergency use in early 2021.
CNBC
Related news
HPAI vaccine bank at the service of epidemic prevention
The National Food Chain Safety Office established an HPAI vaccine…
Read more >MÁOK and Nébih warn about the importance of protection against rabies
Since the beginning of the year, investigations by the National…
Read more >Inaugurated Nébih’s new animal house and high security research laboratory
Dr. Márton Nobilis, Secretary of State for Food and Trade…
Read more >Related news
Using 30% less materials would be a solution to the climate crisis
The circular economy is a global imperative: it transcends geographical…
Read more >The Hégető Honorka Awards were presented for the twentieth time
This year, the Honorka Hégető Awards were presented for the…
Read more >The World Science Forum starts in Budapest today
The World Science Forum (WSF) begins today in Budapest, with…
Read more >